Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial.

Authors:

Abstract
11503Background: No standard therapy is available in China for soft tissue sarcoma (STS) patients progressed after first-line chemotherapy. Anlotinib has shown single-agent activity in a phase II study presented orally at 2016 ASCO. This study aimed at confirming anlotinib’s efficacy and safety in advanced STS patients after failure of standard chemotherapy. Methods: Patients aged 18 years and older with angiogenesis inhibitor naive, histologically proven advanced STS, intolerance or failure to anthracycline-based chemotherapy, at least one measurable lesion according to RECIST 1.1, were eligible. Those patients were randomly assigned (2:1) to receive anlotinib (12 mg per day 2 weeks on and 1 week off) or placebo. The pathologic subtypes enrolled were: synovial sarcoma (SS), alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS) and others. Different pathologic subtypes were also randomly assigned (2:1) to each arm. The primary endpoint was progression-free survival (PFS). This trial was registered with ...